Last reviewed · How we verify
NCT01708993
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Phase 2 trial testing Pemetrexed and Reolysin (and safety run-in) in Non Small Cell Lung Cancer in 166 participants. Completed in 26 September 2018.
26 January 2016
Quick facts
| Lead sponsor | Canadian Cancer Trials Group |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 166 |
| Start date | 10 December 2012 |
| Primary completion | 26 January 2016 |
| Estimated completion | 26 September 2018 |
| Sites | 12 locations across Canada |
Drugs / interventions tested
- Pemetrexed and Reolysin (and safety run-in)
- Pemetrexed — full drug profile →
- Docetaxel and Reolysin — full drug profile →
- Docetaxel (Docetaxel) — full drug profile →
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
Canadian Cancer Trials Group — full company profile →
Who can join
18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to find out if giving reolysin in combination with docetaxel or pemetrexed can offer better results than standard therapy with docetaxel or pemetrexed alone.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular pathways and therapeutic targets in lung cancer.
Shtivelman E, Hensing T, Simon GR, Dennis PA, et al · · 2014 · cited 150× · PMID 24722523 · DOI 10.18632/oncotarget.1891 -
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, et al · · 2015 · cited 106× · PMID 25535693 · DOI 10.1097/jto.0000000000000405 -
Past, Present and Future of Oncolytic Reovirus.
Müller L, Berkeley R, Barr T, Ilett E, et al · · 2020 · cited 97× · PMID 33142841 · DOI 10.3390/cancers12113219 -
Trial watch: Oncolytic viruses for cancer therapy.
Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, et al · · 2013 · cited 96× · PMID 23894720 · DOI 10.4161/onci.24612 -
Trial Watch-Oncolytic viruses and cancer therapy.
Pol J, Buqué A, Aranda F, Bloy N, et al · · 2016 · cited 87× · PMID 27057469 · DOI 10.1080/2162402x.2015.1117740 -
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov DW, Nuovo GJ, Stiff A, Mace T, et al · · 2014 · cited 74× · PMID 25294913 · DOI 10.1158/1078-0432.ccr-14-1404 -
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Pol JG, Lévesque S, Workenhe ST, Gujar S, et al · · 2018 · cited 61× · PMID 30524901 · DOI 10.1080/2162402x.2018.1503032 -
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O, Hoffner B, Gasal E, Hong J, et al · · 2017 · cited 59× · PMID 28712033 · DOI 10.1007/s00262-017-2025-8
Verify or expand the search:
- PubMed search for NCT01708993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Canadian Cancer Trials Group trials
Trials by the same sponsor.
- NCT07390435 — Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials · not yet recruiting
- NCT07297667 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · Phase 1 · not yet recruiting
- NCT06630273 — Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherape · not yet recruiting
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01708993 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Canadian Cancer Trials Group
- Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01708993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing